Humacyte, Inc. (HUMA)
(Real Time Quote from BATS)
$1.74 USD
+0.21 (13.73%)
Updated Sep 18, 2025 12:20 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HUMA 1.74 +0.21(13.73%)
Will HUMA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HUMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HUMA
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
HUMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Other News for HUMA
Humacyte (HUMA) Receives Consistent 'Buy' Rating from D. Boral Capital | HUMA Stock News
HUMA forms Bollinger Band Squeeze on September 17
Humacyte (HUMA) Reveals Promising Preclinical Study Results for CTEV
Humacyte announces preclinical data on CTEV use
Humacyte announces preclinical data on CTEV use